AU7608898A - Ntn-2 member of tnf ligand family - Google Patents

Ntn-2 member of tnf ligand family Download PDF

Info

Publication number
AU7608898A
AU7608898A AU76088/98A AU7608898A AU7608898A AU 7608898 A AU7608898 A AU 7608898A AU 76088/98 A AU76088/98 A AU 76088/98A AU 7608898 A AU7608898 A AU 7608898A AU 7608898 A AU7608898 A AU 7608898A
Authority
AU
Australia
Prior art keywords
human
human ntn
ntn
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU76088/98A
Other languages
English (en)
Inventor
Piotr Masiakowski
David Valenzuela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU7608898A publication Critical patent/AU7608898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU76088/98A 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family Abandoned AU7608898A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4877697P 1997-06-06 1997-06-06
US60048776 1997-06-06
US6638797P 1997-11-21 1997-11-21
US60066387 1997-11-21
PCT/US1998/011294 WO1998055621A1 (en) 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family

Publications (1)

Publication Number Publication Date
AU7608898A true AU7608898A (en) 1998-12-21

Family

ID=26726521

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76088/98A Abandoned AU7608898A (en) 1997-06-06 1998-06-03 Ntn-2 member of tnf ligand family

Country Status (6)

Country Link
EP (1) EP0991759A1 (ja)
JP (1) JP2002517977A (ja)
AU (1) AU7608898A (ja)
CA (2) CA2292899A1 (ja)
IL (1) IL133316A0 (ja)
WO (1) WO1998055621A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US6689579B1 (en) 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
WO1999011791A2 (en) * 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
JP2002503444A (ja) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー リガンドファミリー遺伝子
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
AU1467000A (en) * 1998-11-04 2000-05-22 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A novel tumor necrosis factor family member, drl, and related compositions and methods
GB9828628D0 (en) * 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
ES2329254T3 (es) * 1999-01-07 2009-11-24 Zymogenetics, Inc. Usos terapeuticos de receptores solubles de br43x2.
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CN100340292C (zh) 1999-01-25 2007-10-03 比奥根艾迪克Ma公司 Baff,其封闭剂以及它们在b细胞应答的调节中的应用
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2880400A (en) * 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
EP2314694A3 (en) 1999-08-17 2013-12-11 Biogen Idec MA Inc. BAFF receptor (BCMA), an immunoregulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2408617A1 (en) 2000-05-12 2001-11-22 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
AU6842701A (en) 2000-06-16 2002-01-14 Human Genome Sciences Inc Antibodies that immunospecifically bind to blys
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
RS51708B (sr) 2001-05-11 2011-10-31 Amgen Inc. Peptidi i njima srodni molekuli koji se vezuju za tall-1
DK2116259T3 (da) 2001-05-24 2012-05-21 Zymogenetics Inc TACI-immunoglobulinfusionsproteiner
WO2004094620A2 (en) 2003-03-28 2004-11-04 Biogen Idec Ma Inc. Truncated baff receptors
WO2005051994A2 (en) * 2003-11-21 2005-06-09 Zymogenetics, Inc. Ztnf11, a tumor necrosis factor
EP2332563A3 (en) * 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
JP5118037B2 (ja) 2005-08-09 2013-01-16 ザイモジェネティクス， インコーポレイテッド Ｔａｃｉ融合分子を用いた異常細胞増殖の処置及び予防のための方法
AR059945A1 (es) 2005-08-09 2008-05-14 Zymogenetics Inc Metodos para tratar afecciones malignas de celulas b que utilizan una molecula de fusion taci-ig
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
UA98462C2 (ru) 2006-05-15 2012-05-25 Арес Трейдинг С.А. Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
CN106367714A (zh) 2015-07-24 2017-02-01 先健科技(深圳)有限公司 铁基可吸收植入医疗器械与预制管及其制备方法
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT939804E (pt) * 1996-10-25 2005-11-30 Human Genome Sciences Inc Neutroquina alfa
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents

Also Published As

Publication number Publication date
CA2292835A1 (en) 1998-12-10
JP2002517977A (ja) 2002-06-18
WO1998055621A1 (en) 1998-12-10
EP0991759A1 (en) 2000-04-12
IL133316A0 (en) 2001-04-30
CA2292899A1 (en) 1998-12-10

Similar Documents

Publication Publication Date Title
AU743490B2 (en) NTN-2 member of TNF ligand family
AU7608898A (en) Ntn-2 member of tnf ligand family
US6475987B1 (en) Tall-1 receptor homologues
BG65519B1 (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
EP1019502A2 (en) Human orphan receptor ntr-1
KR100620334B1 (ko) 헤르페스 심플렉스 바이러스 유입 매개체에 대한 리간드및 사용 방법
JP4161084B2 (ja) 腫瘍壊死因子関連リガンド
US20020160451A1 (en) Novel orphan receptors
AU748167B2 (en) Novel nucleic acid and polypeptide
WO1997042321A9 (en) Osteoclast transporter protein
WO1997042321A1 (en) Osteoclast transporter protein
WO1999026980A1 (en) Methods and reagents for the utilization of sap family member proteins, novel signal transduction regulators
WO2000018800A1 (en) Novel secreted immunomodulatory proteins and uses thereof
AU753400C (en) Orphan receptors
US20040180826A1 (en) Novel receptor that causes cell death
US6207413B1 (en) Nucleic acids encoding novel orphan cytokine receptors
MXPA01009491A (es) Moleculas de acido desoxirribonucleico (adn) que codifican para proteinas clax humanas y sus proteinas de fusion solubles.
JPH11215989A (ja) 免疫グロブリン遺伝子スーパーファミリーのメンバー、ｐｉｇｒ−２
JPH1072495A (ja) 免疫関連因子

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted